Drug Patent Term Restoration

Drug Patent Term Restoration (PTR), established by the Hatch-Waxman Act in the U.S., compensates pharmaceutical innovators for patent time lost during the lengthy FDA regulatory review process. The extension is capped at five years, and the total effective patent life post-approval cannot exceed 14 years. This mechanism balances innovation incentives with generic drug competition.

In Enterprise Risk Management (ERM), PTR is a critical tool for mitigating market and financial risks. Securing a patent extension protects a drug's market exclusivity, directly impacting revenue forecasts. Failure to obtain PTR exposes the product to premature generic competition, leading to significant revenue loss. Integrating PTR strategy into IP and market risk frameworks is essential for safeguarding profitability.

Taiwanese enterprises often face challenges with the complex regulations of the FDA and EMA and lack practical experience in filing for PTR. This can lead to missed deadlines or incorrect submissions. The solution involves establishing dedicated regulatory/IP teams and engaging external experts for early-stage strategic planning to ensure compliance and maximize patent value when entering Western markets.

Winners Consulting specializes in Drug Patent Term Restoration for Taiwan enterprises, helping build compliant systems within 90 days.